MX391574B - Partículas coloidales para su uso en medicina. - Google Patents

Partículas coloidales para su uso en medicina.

Info

Publication number
MX391574B
MX391574B MX2018004445A MX2018004445A MX391574B MX 391574 B MX391574 B MX 391574B MX 2018004445 A MX2018004445 A MX 2018004445A MX 2018004445 A MX2018004445 A MX 2018004445A MX 391574 B MX391574 B MX 391574B
Authority
MX
Mexico
Prior art keywords
medicine
colloidal particles
composition
contain
active agent
Prior art date
Application number
MX2018004445A
Other languages
English (en)
Spanish (es)
Other versions
MX2018004445A (es
Inventor
John Mayo
Richard Wolf-Garraway
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of MX2018004445A publication Critical patent/MX2018004445A/es
Publication of MX391574B publication Critical patent/MX391574B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2018004445A 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina. MX391574B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518172.0A GB201518172D0 (en) 2015-10-14 2015-10-14 Colloidal particles for use in medicine
PCT/EP2016/074759 WO2017064276A1 (en) 2015-10-14 2016-10-14 Colloidal particles for use in medicine

Publications (2)

Publication Number Publication Date
MX2018004445A MX2018004445A (es) 2018-08-14
MX391574B true MX391574B (es) 2025-03-21

Family

ID=55131025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004445A MX391574B (es) 2015-10-14 2016-10-14 Partículas coloidales para su uso en medicina.

Country Status (15)

Country Link
US (3) US20190192664A1 (cg-RX-API-DMAC7.html)
EP (1) EP3362039A1 (cg-RX-API-DMAC7.html)
JP (1) JP7160678B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180067616A (cg-RX-API-DMAC7.html)
CN (1) CN108472246A (cg-RX-API-DMAC7.html)
AU (1) AU2016336929B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007399A2 (cg-RX-API-DMAC7.html)
CA (1) CA3036111C (cg-RX-API-DMAC7.html)
EA (1) EA201890703A1 (cg-RX-API-DMAC7.html)
GB (1) GB201518172D0 (cg-RX-API-DMAC7.html)
HK (1) HK1256814A1 (cg-RX-API-DMAC7.html)
IL (1) IL258567B2 (cg-RX-API-DMAC7.html)
MX (1) MX391574B (cg-RX-API-DMAC7.html)
SG (2) SG11201802956RA (cg-RX-API-DMAC7.html)
WO (1) WO2017064276A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115190883A (zh) * 2019-11-07 2022-10-14 伊利诺伊大学评议会 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法
GB202111757D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
GB202111758D0 (en) * 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE179599T1 (de) 1993-08-06 1999-05-15 Opperbas Holding Bv Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
ES2233036T3 (es) 1998-04-27 2005-06-01 Opperbas Holding B.V. Composicion farmaceutica que comprende factor viii y liposomas neutros.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
RU2250911C2 (ru) 1999-07-14 2005-04-27 Элзэ Копэрейшн Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
US20070141135A1 (en) * 2005-06-29 2007-06-21 Balu-Lyer Sathy V Compositions and methods for less immunogenic protein-lipid complexes
US20030232075A1 (en) * 2002-05-06 2003-12-18 University Of Minnesota, A Minnesota Corporation Compositions for producing factor Xa
ATE395101T1 (de) 2003-04-15 2008-05-15 Opperbas Holding Bv Pharmazeutische zusammensetzung, enthaltend proteine und/oder polypeptide sowie kolloidpartikel
EP2437726B1 (en) 2009-06-03 2018-05-16 Sequessome Technology Holdings Limited Formulations for the treatment of deep tissue pain
AU2010283998B2 (en) 2009-08-21 2015-01-29 Targeted Delivery Technologies Limited Vesicular formulations
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
JP6352950B2 (ja) * 2013-03-08 2018-07-04 ノバルティス アーゲー 活性薬物の送達のための脂質と脂質組成物

Also Published As

Publication number Publication date
US20250170244A1 (en) 2025-05-29
GB201518172D0 (en) 2015-11-25
CA3036111A1 (en) 2017-04-20
BR112018007399A2 (pt) 2018-10-16
EP3362039A1 (en) 2018-08-22
SG10202010711UA (en) 2020-12-30
EA201890703A1 (ru) 2018-11-30
IL258567B1 (en) 2025-04-01
HK1256814A1 (zh) 2019-10-04
IL258567B2 (en) 2025-08-01
SG11201802956RA (en) 2018-05-30
US20210093721A1 (en) 2021-04-01
CN108472246A (zh) 2018-08-31
AU2016336929B2 (en) 2022-09-29
US20190192664A1 (en) 2019-06-27
JP2018535952A (ja) 2018-12-06
KR20180067616A (ko) 2018-06-20
IL258567A (en) 2018-05-31
MX2018004445A (es) 2018-08-14
JP7160678B2 (ja) 2022-10-25
AU2016336929A1 (en) 2018-05-10
WO2017064276A1 (en) 2017-04-20
CA3036111C (en) 2023-06-06

Similar Documents

Publication Publication Date Title
SA520411636B1 (ar) صيغ جسيمات نانوية دهنية
CY1124380T1 (el) Συστηματα διαβλεννογονιας και διαδερμικης χορηγησης
MX384021B (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018000705A1 (es) Método de cristalización y biodisponibilidad
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
MX2016014622A (es) Sistemas de suministro de medicamentos y metodos de uso relacionados.
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
WO2016040887A3 (en) Multilamellar lipid vesicle compositions and methods of use
MX386234B (es) Vacuna para la malaria.
SG10201902407PA (en) Injectable microparticles for hyper-localized release of therapeutic agents
MX382580B (es) Formulaciones de liberación inmediata disuasivas de abuso que comprenden polisacáridos no celulósicos.
MX391574B (es) Partículas coloidales para su uso en medicina.
MX2018005456A (es) Capsulas de liberación prolongada recubiertas con película.
MX2020007293A (es) Compuestos desuterados, composiciones y metodos para tratar canceres asociados con la activacion etbr.
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
WO2014165513A3 (en) Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof
CU20180110A7 (es) Una composición que comprende pic para el tratamiento del cáncer
BR112017006918A2 (pt) formulações nanoestruturadas para liberação de silibinina e outros ingredientes ativos para o tratamento de doenças oculares
PH12018501991A1 (en) Pharmaceutical composition for use in treating fibrosis
MX2017004378A (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
MX377823B (es) Composición nasal con capacidades de formación de película.
FI20155045A7 (fi) Havupuun pihka steriilin tulehduksen hoitamiseksi ja ennaltaehkäisemiseksi
ES2502140T1 (es) Comprimidos de liberación inmediata de rasagilina hemitartrato
AR105728A1 (es) Lisobactina para su uso en el tratamiento de la mastitis bovina